Longevity Clinic Outcomes Scorecard: What Counts as Progress? (2026)

Reviewed August 27, 2026. This scorecard is a WLC editorial tool for asking better questions. It is not a validated outcome instrument, clinic certification, medical guideline, or prediction of lifespan.

Quick answer

A clinic has not produced a health outcome merely because it completed many tests, found an abnormality, or moved a proprietary score. The FDA-NIH BEST glossary makes a crucial distinction:

• a biomarker indicates a biological process or response;
• a clinical outcome reflects how a person feels, functions, or survives.¹

Both can matter, but they answer different questions. A useful clinic report should therefore separate:

1. Process: Was the promised assessment, referral, or follow-up completed?
2. Biomarker: Did a decision-relevant measurement change using a comparable method?
3. Function: Did strength, fitness, mobility, cognition, sleep, or another validated measure change?
4. Patient-important outcome: Did symptoms, daily function, quality of life, or a clinically important event change?
5. Safety and burden: Were harms, false positives, side effects, costs, and treatment burden recorded?

This page is about what counts as progress. Our follow-up plan guide covers who owns abnormal findings and how the handoff should work.

The outcome map to request

Ask the clinic to show, before purchase, how it maps each major service to an outcome.

Service or claim	Weak evidence of value	More useful evidence
Comprehensive assessment	Number of tests completed	Prioritized findings, completed referrals, changed decisions
Cardiometabolic program	A dashboard score	Confirmed blood pressure and guideline-relevant risk markers, with treatment tolerance
Fitness program	Sessions attended	Comparable fitness or performance measures plus everyday function
Sleep program	Wearable sleep score	Symptoms, adherence, appropriate clinical evaluation, and validated measures when indicated
Biological-age testing	Younger proprietary age	Reproducible method, uncertainty, and a separate record of conventional outcomes
Imaging package	Findings detected	Appropriate resolution of important findings and burden caused by incidental ones
AI monitoring	Alerts generated	Useful escalations, human review, false alerts, missed events, and resulting decisions

If the clinic cannot define the outcome before testing begins, it can select whichever number looks favourable afterward.

A non-certifying scorecard

For each domain below, record one of three states. Do not add the states into an overall clinic grade.

• 0, absent: no defined measure, owner, comparison method, or follow-up.
• 1, partial: something is measured, but the decision pathway, comparability, or patient relevance is unclear.
• 2, documented: baseline, method, target question, review interval, clinical owner, and resulting decision are recorded.

The numbers are navigation aids, not evidence weights. A zero for urgent-result escalation, adverse-event tracking, or records access is a critical gap regardless of performance elsewhere. A clinic cannot compensate for missing safety controls by offering more biomarkers.

Domain	What documented performance looks like
Clinical ownership	A named licensed professional signs the plan and owns escalation
Referral completion	Important findings are tracked until handoff or a documented decision not to proceed
Conventional risk	Comparable, decision-relevant measurements and treatment context are retained
Function	The same appropriate method is used at baseline and follow-up
Patient-reported impact	Symptoms, daily function, or quality of life are captured where relevant
Safety	Adverse effects, false positives, and treatment burden are actively reviewed
Data access	Patients can export source results, reports, and the action history

What to track by domain

Cardiometabolic risk

Track only measurements that connect to a clinical question. Depending on the person, these may include confirmed blood pressure, lipids, glucose regulation, smoking status, kidney function, medication effects, and physical activity. Record changes in treatment and tolerability alongside the number. A biomarker improvement without knowing how it was obtained can hide side effects or unsustainable burden.

Body composition

Body weight, waist measurement, and body-composition methods answer related but different questions. If a clinic repeats DXA or another method, ask whether the same device, protocol, and conditions are used. The report should not imply that a small change below the method’s practical precision proves a meaningful outcome.

Fitness and physical function

Cardiorespiratory fitness is associated with long-term outcomes in observational research, but a clinic still needs an appropriate, repeatable test and a safe interpretation.² Strength, balance, gait, or other performance measures may be more relevant for some patients. Record whether the change improved actual activity or daily function, not only test performance.

Sleep and recovery

Wearables can help track trends, but sleep stages and recovery scores are device-dependent estimates. A useful outcome record includes symptoms, function, adherence to an agreed plan, and clinical evaluation when a disorder such as sleep apnea is suspected. A better wearable score alone is not proof that a sleep disorder resolved.

Cognitive and brain-health testing

A screening score is not a diagnosis. Track the measurement method, relevant symptoms, medication or sensory factors, referral completion, and how the result changed care. Repeated testing can also be affected by familiarity with the test.

Imaging findings

Count both benefit and burden. A clinic should record which findings were clinically important, which needed comparison or specialist review, which remained unresolved, and which generated unnecessary procedures or anxiety. The American College of Radiology warns that total-body MRI screening in asymptomatic people can produce nonspecific findings and unnecessary follow-up.³

Biological-age and omics tests

These can be exploratory biomarkers. They are not direct measures of how a person feels, functions, or survives. If tracked, the clinic should name the assay, version, biological sample, uncertainty, and pre-analytic conditions. It should report conventional outcomes separately and avoid using a changed age score as proof of age reversal.

Dashboards and AI

Measure the workflow, not the interface. Useful outcomes include clinically relevant alerts reviewed, response time, false alerts, missed escalation, decisions changed, and patient burden. The FDA’s list of AI-enabled medical devices is a resource for identifying authorized devices; it does not make every algorithm used by a longevity clinic validated for every claim.⁴

A 30, 90, and 365-day evidence record

Fixed dates are useful for organizing records, but they are not universal retesting schedules.

Around 30 days

• Have urgent findings and medication issues been addressed?
• Were source reports delivered?
• Does every important action have an owner?
• Were harms or unexpected burdens recorded?

Around 90 days

• Which agreed actions were completed and tolerated?
• Which outcomes can reasonably be compared now?
• Were referrals completed?
• Did the plan change in response to evidence?

Around 365 days

• Which changes persisted?
• Did function or patient-important outcomes improve?
• What cost, treatment burden, and adverse effects accumulated?
• Which tests added no useful decision and should not be repeated?

For each measurement, the clinic should justify the interval. Some findings require faster action; others should not be repeated annually by default.

Critical red flags

• The clinic calls test completion an outcome.
• A proprietary score is the only proof of success.
• Biological age is presented as lifespan gained.
• Improved biomarkers are reported without methods, medications, side effects, or comparability.
• Incidental findings disappear from the record once referred elsewhere.
• Only favourable changes are shown.
• Safety, false positives, and treatment burden are not measured.
• The clinic changes the assay or algorithm without flagging the break in the trend.
• A numeric score is marketed as independent certification.

Buyer checklist

1. Which outcomes are defined before the program begins?
2. Which are process measures, biomarkers, functional measures, or patient-reported outcomes?
3. Which methods will be repeated, and how will comparability be protected?
4. Who reviews deterioration, side effects, and unresolved referrals?
5. Are false positives and unnecessary follow-up included in the result?
6. Can I see my raw data and the history of clinical decisions?
7. Will you report a neutral result, or only improvements?
8. Which claimed benefits remain exploratory?
9. What would make you stop a test or treatment?
10. How will you know whether the program was worth its cost and burden?

Bottom line

The strongest outcome system does not promise to prove longer life in a year. It records what was done, what changed, whether the change mattered to health or function, what harms occurred, and how each result changed a decision.

Use biomarker trends as one layer of evidence. Do not let them replace clinical outcomes, patient experience, safety, or accountable follow-up.

FAQ

How do you measure longevity clinic outcomes?

Use several layers: process completion, decision-relevant biomarkers, functional measures, patient-important outcomes, and safety or burden. Define each measure before the program starts and preserve the method, timing, and clinical context.

Are biological-age tests good follow-up outcomes?

They can be exploratory biomarkers, but they should not be the primary proof of success. They do not directly show how a person feels, functions, or survives and should not be presented as years of life gained.

What should happen after abnormal imaging?

The record should show urgency, clinical owner, specialist review or comparison, transfer of images, resolution status, costs, and any harm caused by unnecessary follow-up.

Are annual longevity memberships worth it?

They may be when continuity produces accountable decisions, completed referrals, comparable measurements, and useful records. Repeated testing or dashboard access alone does not establish value.

What is the biggest outcome red flag?

A clinic that defines success only through its own proprietary score. The reader should be able to distinguish testing activity, biological signals, real-world function, patient experience, and harm.

Sources

Footnotes

1. FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource. Glossary last revised January 16, 2025. Accessed August 27, 2026. ↩

2. Mandsager K, et al. Association of Cardiorespiratory Fitness With Long-term Mortality Among Adults Undergoing Exercise Treadmill Testing. JAMA Network Open. 2018. ↩

3. American College of Radiology. Statement on Screening Total Body MRI. Accessed August 27, 2026. ↩

4. U.S. Food and Drug Administration. Artificial Intelligence-Enabled Medical Devices. Content current June 16, 2026. Accessed August 27, 2026. ↩